NANAIMO, Uk Columbia–(BUSINESS WIRE)–Tilray, Inc. (NASDAQ: TLRY), a pioneer that is global cannabis research, cultivation, production, and distribution, today announced it has agreed with Worldpharma Biotech (“Worldpharma”), through its wholly-owned subsidiary Tilray Portugal Unipessoal Lda. (“Tilray Portugal”), to export good processes that are manufacturingGMP) certified medical cannabis from Portugal to Spain. The delivery marks the initial medical cannabis import into Spain by Worldpharma and also the 17(* that is*)th( country to receive Tilray medical cannabis worldwide.The Agencia Española de Medicamentos y Productos Sanitorios (AEMPS), Spain’s food and drug administration, has approved Worldpharma to import Tilray’s GMP-certified cannabis that are medical natural product from the Portugal center to Spain. With Tilray’s pharmaceutical-grade cannabis, Worldpharma will establish cannabis that are medical for clinical trials in Spanish Hospitals for diseases such as Alzheimer’s, Parkinson’s disease, and skin inflammation.
Brendan Kennedy, Tilray’s Chief Executive Officer, said, “We’re incredibly honored to be the cannabis that are first become authorized and also to deliver medical cannabis into Spain. We are grateful to partner with the AEMPS and established pharmaceutical leaders such as Worldpharma Biotech on the distribution of Tilray medical cannabis.”
Juan as we continue to work with regulators around the world Jose Garcia Miquel, Founder of World Pharma Biotech, said, “We are very happy to initiate a cannabis biomass supply agreement with Tilray to supply our extraction and purification lab with quality GMP products that are certified meet up with the greatest of E.U. and Spanish Pharmacology guidelines. We want to utilize the businesses with all the quality that is highest pharmaceutical standards to give doctors and patients total confidence. It’s been impossible to reach this known quality level off their cannabis authorized organizations in Spain.”
Sascha Mielcarek, Tilray’s General Manager for European countries, stated, “We have become very happy to partner with Worldpharma. Tilray is once more developing it self as an integral player with solid expertise into the ongoing service of patient well-being. Throughout its supply chain, Tilray applies the highest medical standards that provide sustainable and access that is safe pharmaceutical-grade medical cannabis for clients in need of assistance, paving just how for future medical cannabis requirements of care.”
Tilray has a pioneering track record as a business dedicated to making GMP-certified, pharmaceutical-grade medical cannabis items offered to clients in need of assistance internationally and had been the first ever to effectively export medical cannabis from the united states and import medical cannabis items in to the E.U. in 2016.
Tilray’s E.U. Campus in Portugal is a production that is multi-faceted that includes research and quality control labs, packaging, and distribution sites for medical cannabis. It also serves as a hub supporting Tilray’s research that is clinical item development efforts across European countries. Tilray has built product sales and circulation plans to produce medical cannabis through major distribution that is pharmaceutical throughout Germany and the E.U., which will serve as a means to allowing patients to access Tilray’s GMP-certified finished medical cannabis.
Tilray is a pioneer that is global the investigation, cultivation, manufacturing, and circulation of cannabis and cannabinoids, presently serving tens and thousands of clients and customers in 17 nations spanning five continents.
About WorldPharma Biotech
World Pharma Biotech had been launched in 2014 in Valencia, Spain, dedicated to vegetal components for nutraceuticals, cosmetic makeup products, and industries that are pharmaceutical. The company is located in the Scientific Park of the University of Valencia, a center of Spin-off and companies that are start-up Valencia University. The removal and purification lab’s focus that is primary the manufacturing of Active Pharmaceutical Ingredients from Cannabis for the European Pharmaceutical and Dermo Cosmetic Industry.
This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and information that is“forward-looking in the meaning of Canadian securities regulations, or collectively, forward-looking statements. Forward-looking statements in this news release could be identified by way of terms such as for example, “may”, “would”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook” along with other expressions that are similar. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions, and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, including assumptions in respect of current and future market that is european, the existing and future regulatory environment and future approvals and licenses. Real outcomes, performance, or accomplishment could vary materially from that expressed in, or suggested by, any forward-looking statements in this news release, and, correctly, you ought not put reliance that is undue any such forward-looking statements, and they are not guarantees of future results. Please see the heading “Risk Factors” in Tilray’s Quarterly Report on Form 10-Q, which was filed with the Securities and Exchange Commission on November 9, 2020, for a discussion of the material risk factors that could cause actual results to differ materially from the information that is forward-looking. Tilray will not undertake to upgrade any statements that are forward-looking are included herein, except relative to relevant securities guidelines.
Get Real-Time Updates from MJobserver.com